ABEO

$4.76

Post-MarketAs of Mar 17, 8:00 PM UTC

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.76
Potential Upside
743.4%
Whystock Fair Value$40.15
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with reces...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$257.95M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.93
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
75.90%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
9.41

Recent News

GuruFocus.com
Mar 17, 2026

Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ...

Abeona Therapeutics Inc (ABEO) reports growing patient demand and significant financial gains, despite facing operational hurdles in launching its groundbreaking gene therapy.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 17, 2026

Abeona Therapeutics Q4 Earnings Call Highlights

Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), while outlining early commercial tractio

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 17, 2026

Abeona (ABEO) Q4 2025 Earnings Call Transcript

Treating our first commercial patient this past December was a significant milestone for Abeona Therapeutics Inc., but 2026 is where the launch execution ramps up. All patient treatments and biopsies performed to date have come from the first two of our four qualified treatment centers, Lurie Children's Hospital in Chicago and Lucile Packard Children's Hospital at Stanford. This momentum provides Abeona Therapeutics Inc. an opportunity to demonstrate that the operational machine behind ZevaSkin works at scale from initial biopsy through final delivery.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Mar 17, 2026

Abeona Therapeutics: Q4 Earnings Snapshot

CLEVELAND (AP) — Abeona Therapeutics Inc. ABEO) on Tuesday reported a loss of $20.5 million in its fourth quarter. On a per-share basis, the Cleveland-based company said it had a loss of 34 cents.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Mar 10, 2026

Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026

Abeona Therapeutics (NASDAQ:ABEO) executives said the commercial launch of ZEVASKYN is gaining momentum after an early manufacturing-related delay, outlining progress on treatment center activation, patient onboarding, and capacity expansion during remarks at the Leerink Partners Global Healthcare C

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.